Advertisement

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

      Abstract

      Background: Recent reports describe discontinuation-emergent adverse events upon cessation of selective serotonin reuptake inhibitors including dizziness, insomnia, nervousness, nausea, and agitation. We hypothesized that interruption of fluoxetine treatment would be associated with fewer discontinuation-emergent adverse events than interruption of sertraline or paroxetine treatment, based on fluoxetine’s longer half-life.
      Methods: In this 4-week study, 242 patients with remitted depression receiving maintenance therapy with open-label fluoxetine, sertraline, or paroxetine for 4–24 months had their maintenance therapy interrupted with double-blind placebo substitution for 5–8 days. The Symptom Questionnaire (SQ), the Discontinuation-Emergent Signs and Symptoms checklist, the 28-item Hamilton Depression Rating Scale, and the Montgomery–Asberg Depression Rating Scale were used to assess somatic distress and stability of antidepressant response.
      Results: Two hundred twenty patients (91%) completed the study. Following interruption of therapy, fluoxetine-treated patients experienced fewer discontinuation-emergent events than either sertraline-treated or paroxetine-treated patients (p < .001). The mean SQ somatic symptom scale score in fluoxetine-treated patients was significantly lower than that in sertraline-treated and paroxetine-treated patients (p < .001). Fluoxetine-treated patients also experienced less reemergence of depressive symptoms than sertraline-treated or paroxetine-treated patients (p < .001).
      Conclusions: Abrupt interruption of antidepressant therapy for 5–8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetine.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barr L.C
        • Goodman W.K
        • Price L.H
        Physical symptoms associated with paroxetine discontinuation [letter].
        Am J Psychiatry. 1994; 151: 289
        • Bhaumik S
        • Wildgust H.J
        Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders [letter].
        Hum Psychopharmacol. 1996; 11: 337-338
        • Buckalew L.W
        • Sallis R.E
        Patient compliance and medication perception.
        J Clin Psychol. 1986; 42: 49-53
        • Ceccherini-Nelli A
        • Bardellini L
        • Cur A
        • Guazzelli M
        • Maggini C
        • Dilsaver S.C
        Antidepressant withdrawal.
        Am J Psychiatry. 1993; 150: 165
        • Charney D.S
        • Heninger G.R
        • Sternberg D.E
        • Landis H
        Abrupt discontinuation of tricyclic antidepressant drugs.
        Br J Psychiatry. 1982; 141: 377-386
        • Coupland N.J
        • Bell C.J
        • Potokar J.P
        Serotonin reuptake inhibitor withdrawal.
        J Clin Psychopharmacol. 1996; 16: 356-362
        • Demyttenaere K
        • Van Ganse E
        • Gregoire J
        • Gaens E
        • Masters P
        Compliance in depressed patients treated with fluoxetine or amitriptyline.
        Int Clin Psychopharmacol. 1997; 13: 11-17
        • Dilsaver S.C
        • Greden J.F
        Antidepressant withdrawal phenomena.
        Biol Psychiatry. 1984; 19: 237-256
        • Dilsaver S.C
        • Feinberg M
        • Greden J.F
        Antidepressant withdrawal symptoms treated with anticholinergic agents.
        Am J Psychiatry. 1983; 140: 249-251
        • Dilsaver S.C
        • Greden J.J
        • Snider R.M
        Antidepressant withdrawal syndromes.
        Int Clin Psychopharmacol. 1987; 2: 1-19
        • Einbinder E
        Fluoxetine withdrawal? [letter].
        Am J Psychiatry. 1995; 152: 1235
        • Fava G.A
        • Grandi S
        Withdrawal syndromes after paroxetine and sertaline discontinuation [letter].
        J Clin Psychopharmacol. 1995; 15: 374-375
        • Frost L
        • Lal S
        Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter].
        Am J Psychiatry. 1995; 152: 810
      1. Gillespie C, Wildgust HJ, Haddad P, Currie A (1996): SSRIs and withdrawal syndrome [abstract]. World Congress of Psychiatry, Madrid, August 23–28.

        • Hamilton M
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Kasantikul D
        Reversible delirium after discontinuation of fluoxetine.
        J Med Assoc Thai. 1995; 78: 53-54
        • Kellner R
        A symptom questionnaire.
        J Clin Psychiatry. 1987; 48: 268-274
        • Kellner R
        The development of sensitive scales for research in therapeutics.
        in: Fava M Rosenbaum J.F Research Designs and Methods in Psychiatry. Elsevier, New York1992: 213-222
        • Keuthen N.J
        • Cyr P
        • Ricciardi J.A
        • Minichiello W.E
        • Buttolph M.L
        • Jenike M.A
        Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter].
        J Clin Psychopharmacol. 1994; 14: 206-207
        • Koopowitz L.F
        • Berk M
        Paroxetine induced withdrawal effects.
        Hum Psychopharmacol. 1995; 10: 147-148
        • Lazowick A.L
        • Levin G.M
        Potential withdrawal syndrome associated with SSRI discontinuation.
        Ann Pharmacother. 1995; 29: 1284-1285
      2. Lejoyeux M, Adès J, Mourad I, Solomon J, Dilsaver S (1996): Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs 278–292.

        • Leiter F.L
        • Nierenberg A.A
        • Sanders K.M
        • Stern T.A
        Discontinuation reactions following sertraline.
        Biol Psychiatry. 1995; 38: 694-695
        • Louie A.K
        • Lannon R.A
        • Ajari L.J
        Withdrawal reaction after sertraline discontinuation [letter].
        Am J Psychiatry. 1994; 151: 450-451
        • Mallya G
        • White K
        • Gunderson C
        Is there a serotonergic withdrawal syndrome? [letter].
        Biol Psychiatry. 1993; 33: 851-852
        • Montgomery S.A
        • Asberg M
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Montgomery S.A
        • Henry J
        • McDonald G
        • Dinan T
        • Lader M
        • Hindmarch I
        • et al.
        Selective serotonin reuptake inhibitors.
        Int Clin Psychopharmacol. 1994; 9: 47-53
        • Oehrberg S
        • Christiansen P.E
        • Behnke K
        • Borup A.L
        • Severin B
        • Soegaard J
        • et al.
        Paroxetine in the treatment of panic disorder.
        Br J Psychiatry. 1995; 167: 374-379
        • Olivier-Martin R
        Facteurs psychologiques, observance et resistance aux traitements antidepresseurs (Psychological factors, compliance and resistance to antidepressant treatment) (abstract in English).
        Encephale. 1986; 12: 197-203
        • Petersen R.C
        • Richelson E
        Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells.
        Psychopharmacology (Berl). 1982; 76: 26-28
        • Price J.S
        • Waller P.C
        • Wood S.M
        • Mackay A.V.P
        A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
        Br J Clin Pharmacol. 1996; 42: 757-763
        • Pyke R.E
        Paroxetine withdrawal syndromes (letter).
        Am J Psychiatry. 1995; 152: 149-150
        • Rothschild A.J
        Selective serotonin reuptake inhibitor-induced sexual dysfunction.
        Am J Psychiatry. 1995; 152: 1514-1516
        • Stoukides J.A
        • Stoukides C.A
        Extrapyramidal symptoms upon discontinuation of fluoxetine (letter).
        Am J Psychiatry. 1991; 148: 1263
        • Thompson D
        • Buesching D
        • Gregor K.J
        • Oster G
        Patterns of antidepressant use and their relation to costs of care.
        Am J Managed Care. 1996; 2: 1239-1246
        • Tollefson G.D
        • Senogles S.E
        • Frey II, W.H
        • Tuason V.B
        • Nicol S.E
        A comparison of peripheral and central human muscarinic receptor affinities for psychotropic drugs.
        Biol Psychiatry. 1982; 17: 555-567
        • van Harten J
        Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
        Clin Pharmacokinet. 1993; 24: 203-220
        • Young J.L
        • Zonana H.V
        • Shepler L
        Medication noncompliance in schizophrenia.
        Bull Am Acad Psychiatry Law. 1986; 14: 105-122
        • Zajecka J
        • Fawcett J
        • Amsterdam J
        • Quitkin F
        • Reimherr F
        • Rosenbaum J
        • et al.
        Safety of abrupt discontinuation of fluoxetine.
        J Clin Psychopharmacol. 1998; 18: 193-197